Xie Xian Kuan, Zhao Xiao Jiao, Li Run Hua, Cheng Yong Ran, Bing Xin, Yang Jun, Wang Liang You, Zhu Hui Jun, Chen Tian Hui, Chen Jin Fei
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310053, China.
These authors contribute equally to this work.
World J Oncol. 2024 Aug;15(4):675-681. doi: 10.14740/wjon1875. Epub 2024 Jul 5.
While timely assessment of long-term survival for patients with bone cancer is essential for evaluation on early detection and prognosis level of treatment of bone cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long-term survival for patients with bone cancer in Eastern China.
Patients diagnosed with bone cancer during 2004 - 2018 from four cancer registries with high-quality data from Taizhou, Eastern China were included. Five-year relative survival (RS) of bone cancer patients was calculated by period analysis for overall and the stratification. We further predicted 5-year RS during upcoming 2019 - 2023 using a model-based period analysis and survival data during 2004 - 2018.
Overall, 5-year RS for patients with bone cancer during 2014 - 2018 reached 46.6%, being 40.8% for male and 51.0% for female. Five-year RS declined along with aging, decreasing from 58.9% for age < 45 years to 41.5% for age > 60 years, while 5-year RS for urban area was higher compared to rural area (59.1% vs. 44.3%). The 5-year RS during upcoming 2019 - 2023 reached 48.3%. We found a clear upward trend in 5-year RS during 2004 - 2023 for overall and the stratification by sex, age at diagnosis, and region.
We found that, for first time in China using period analysis, most up-to-date 5-year RS for patients with bone cancer reached 46.6% during 2014 - 2018, and is projected to reach 48.3% for the period 2019 - 2023, which has important implications for timely evaluation on early detection and prognosis level of treatment for patients with bone cancer in Eastern China.
虽然及时评估骨癌患者的长期生存率对于评估骨癌的早期发现和治疗预后水平至关重要，但在中国，这些数据极其匮乏。我们旨在及时、准确地评估中国东部骨癌患者的长期生存率。
纳入2004年至2018年期间在中国东部台州四个拥有高质量数据的癌症登记处诊断为骨癌的患者。通过总体和分层的时期分析计算骨癌患者的五年相对生存率（RS）。我们进一步使用基于模型的时期分析和2004年至2018年期间的生存数据预测了2019年至2023年即将到来期间的五年RS。
总体而言，2014年至2018年期间骨癌患者的五年RS达到46.6%，男性为40.8%，女性为51.0%。五年RS随年龄增长而下降，从年龄<45岁时的58.9%降至年龄>60岁时的41.5%，而城市地区的五年RS高于农村地区（59.1%对44.3%）。2019年至2023年即将到来期间的五年RS达到48.3%。我们发现，在2004年至2023年期间，总体以及按性别、诊断时年龄和地区分层的五年RS呈明显上升趋势。
我们发现，在中国首次使用时期分析，2014年至2018年期间骨癌患者最新的五年RS达到46.6%，预计2019年至2023年期间将达到48.3%，这对于及时评估中国东部骨癌患者的早期发现和治疗预后水平具有重要意义。
